mTOR kinase inhibitor sensitizes T-cell lymphoblastic leukemia for chemotherapy-induced DNA damage via suppressing FANCD2 expression

被引：13
作者：
Guo, F. [1 ]
Li, J. [1 ]
Zhang, S. [1 ]
Du, W. [1 ]
Amarachintha, S. [1 ]
Sipple, J. [1 ]
Phelan, J. [2 ]
Grimes, H. L. [2 ]
Zheng, Y. [1 ]
Pang, Q. [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Div Expt Hematol & Canc Biol, Cincinnati, OH 45229 USA
[2] Cincinnati Childrens Hosp Med Ctr, Div Immunobiol, Cincinnati, OH 45229 USA
来源：
LEUKEMIA | 2014年 / 28卷 / 01期
关键词：
MAMMALIAN TARGET; RAPAMYCIN; PATHWAY; CANCER;
D O I：
10.1038/leu.2013.215
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：203 / 206
页数：4
相关论文
共 15 条
  • [1] The mTOR Pathway: A New Target in Cancer Therapy
    Ciuffreda, L.
    Di Sanza, C.
    Incani, U. C.
    Milella, M.
    [J]. CURRENT CANCER DRUG TARGETS, 2010, 10 (05) : 484 - 495
  • [2] Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia
    Evangelisti, C.
    Ricci, F.
    Tazzari, P.
    Tabellini, G.
    Battistelli, M.
    Falcieri, E.
    Chiarini, F.
    Bortul, R.
    Melchionda, F.
    Pagliaro, P.
    Pession, A.
    McCubrey, J. A.
    Martelli, A. M.
    [J]. LEUKEMIA, 2011, 25 (05) : 781 - 791
  • [3] Reduced VEGF Production, Angiogenesis, and Vascular Regrowth Contribute to the Antitumor Properties of Dual mTORC1/mTORC2 Inhibitors
    Falcon, Beverly L.
    Barr, Sharon
    Gokhale, Prafulla C.
    Chou, Jeyling
    Fogarty, Jennifer
    Depeille, Philippe
    Miglarese, Mark
    Epstein, David M.
    McDonald, Donald M.
    [J]. CANCER RESEARCH, 2011, 71 (05) : 1573 - 1583
  • [4] Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling Symphony
    Foster, Kathryn G.
    Fingar, Diane C.
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (19) : 14071 - 14077
  • [5] Defining the role of mTOR in cancer
    Guertin, David A.
    Sabatini, David M.
    [J]. CANCER CELL, 2007, 12 (01) : 9 - 22
  • [6] mTOR regulates DNA damage response through NF-κB-mediated FANCD2 pathway in hematopoietic cells
    Guo, F.
    Li, J.
    Du, W.
    Zhang, S.
    O'Connor, M.
    Thomas, G.
    Kozma, S.
    Zingarelli, B.
    Pang, Q.
    Zheng, Y.
    [J]. LEUKEMIA, 2013, 27 (10) : 2040 - 2046
  • [7] The Akt-mTOR tango and its relevance to cancer
    Hay, N
    [J]. CANCER CELL, 2005, 8 (03) : 179 - 183
  • [8] The PP242 Mammalian Target of Rapamycin (mTOR) Inhibitor Activates Extracellular Signal-regulated Kinase (ERK) in Multiple Myeloma Cells via a Target of Rapamycin Complex 1 (TORC1)/Eukaryotic Translation Initiation Factor 4E (eIF-4E)/RAF Pathway and Activation Is a Mechanism of Resistance
    Hoang, Bao
    Benavides, Angelica
    Shi, Yijiang
    Yang, Yonghui
    Frost, Patrick
    Gera, Joseph
    Lichtenstein, Alan
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2012, 287 (26) : 21796 - 21805
  • [9] Molecular pathogenesis and clinical management of Fanconi anemia
    Kee, Younghoon
    D'Andrea, Alan D.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2012, 122 (11) : 3799 - 3806
  • [10] A Phase I Study of the Mammalian Target of Rapamycin Inhibitor Sirolimus and MEC Chemotherapy in Relapsed and Refractory Acute Myelogenous Leukemia
    Perl, Alexander E.
    Kasner, Margaret T.
    Tsai, Donald E.
    Vogl, Dan T.
    Loren, Alison W.
    Schuster, Stephen J.
    Porter, David L.
    Stadtmauer, Edward A.
    Goldstein, Steven C.
    Frey, Noelle V.
    Nasta, Sunita D.
    Hexner, Elizabeth O.
    Dierov, Jamil K.
    Swider, Cezary R.
    Bagg, Adam
    Gewirtz, Alan M.
    Carroll, Martin
    Luger, Selina M.
    [J]. CLINICAL CANCER RESEARCH, 2009, 15 (21) : 6732 - 6739
12